Anti-cancer Lead Molecule

Handle URI:
http://hdl.handle.net/10754/594844
Title:
Anti-cancer Lead Molecule
Authors:
Sagar, Sunil; Kaur, Mandeep; Esau, Luke E.
Assignee:
King Abdullah University of Science and Technology
Abstract:
Derivatives of plumbagin can be selectively cytotoxic to breast cancer cells. Derivative `A` (Acetyl Plumbagin) has emerged as a lead molecule for testing against estrogen positive breast cancer and has shown low hepatotoxicity as well as overall lower toxicity in nude mice model. The toxicity of derivative `A` was determined to be even lower than vehicle control (ALT and AST markers). The possible mechanism of action identified based on the microarray experiments and pathway mapping shows that derivative `A` could be acting by altering the cholesterol-related mechanisms. The low toxicity profile of derivative `A` highlights its possible role as future anti-cancer drug and/or as an adjuvant drug to reduce the toxicity of highly toxic chemotherapeutic drugs
KAUST Department:
Computational Bioscience Research Center (CBRC); Technology Transfer
Issue Date:
17-Apr-2014
Submitted date:
2013-03-13
Type:
Patent
Application Number:
US 20140107196 A1
Patent Status:
Published Application
Additional Links:
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220140107196%22.PGNR.&OS=DN/20140107196&RS=DN/20140107196; http://assignment.uspto.gov/#/search?adv=publNum:20140107196; http://www.google.com/patents/US20140107196; http://worldwide.espacenet.com/publicationDetails/biblio?CC=US&NR=2014107196A1&KC=A1&FT=D
Appears in Collections:
Patents; Computational Bioscience Research Center (CBRC)

Full metadata record

DC FieldValue Language
dc.contributor.authorSagar, Sunilen
dc.contributor.authorKaur, Mandeepen
dc.contributor.authorEsau, Luke E.en
dc.date.accessioned2016-01-26T10:37:02Zen
dc.date.available2016-01-26T10:37:02Zen
dc.date.issued2014-04-17en
dc.date.submitted2013-03-13en
dc.identifier.urihttp://hdl.handle.net/10754/594844en
dc.description.abstractDerivatives of plumbagin can be selectively cytotoxic to breast cancer cells. Derivative `A` (Acetyl Plumbagin) has emerged as a lead molecule for testing against estrogen positive breast cancer and has shown low hepatotoxicity as well as overall lower toxicity in nude mice model. The toxicity of derivative `A` was determined to be even lower than vehicle control (ALT and AST markers). The possible mechanism of action identified based on the microarray experiments and pathway mapping shows that derivative `A` could be acting by altering the cholesterol-related mechanisms. The low toxicity profile of derivative `A` highlights its possible role as future anti-cancer drug and/or as an adjuvant drug to reduce the toxicity of highly toxic chemotherapeutic drugsen
dc.relation.urlhttp://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220140107196%22.PGNR.&OS=DN/20140107196&RS=DN/20140107196en
dc.relation.urlhttp://assignment.uspto.gov/#/search?adv=publNum:20140107196en
dc.relation.urlhttp://www.google.com/patents/US20140107196en
dc.relation.urlhttp://worldwide.espacenet.com/publicationDetails/biblio?CC=US&NR=2014107196A1&KC=A1&FT=Den
dc.titleAnti-cancer Lead Moleculeen
dc.typePatenten
dc.contributor.departmentComputational Bioscience Research Center (CBRC)en
dc.contributor.departmentTechnology Transferen
dc.description.statusPublished Applicationen
dc.contributor.assigneeKing Abdullah University of Science and Technologyen
dc.description.countryUnited Statesen
dc.identifier.applicationnumberUS 20140107196 A1en
All Items in KAUST are protected by copyright, with all rights reserved, unless otherwise indicated.